In parallel, conjugation with neratinib also reveals synergistic antiproliferative effects, particularly noticeable in the FMCm and FMCp cell lines [10], being this protocol recommended for human metastatic HER2-positive and triple-negative breast cancer therapy [142,143]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.